Skip to content
On November 9, the U.S. Food and Drug Administration (FDA) approved the first-ever vaccine against the chikungunya virus, a mosquito-borne disease that can be […]
FDA approves first vaccine for chikungunya virus Read More »
In September, the Food and Drug Administration (FDA) announced priority review of sotatercept, Merck’s activin signaling inhibitor for the treatment of adults with pulmonary
A promising new treatment for patients with pulmonary arterial hypertension Read More »
Pharmacy benefit managers, or PBMs, have been in the political hot seat for a couple of years now—and for good reason. “Every day PBMs
As PBM reform maintains steam, biotech companies and patients are urged to take action Read More »
The proposed updated European Union General Pharmaceutical Legislation offers some opportunities but also creates some new threats for biotech—and when it becomes law in
Proposed EU Pharma Law features good intentions and bad ideas, says BIO-Europe panel Read More »
As weakening investment plagues small, innovative biotechs on both sides of the Atlantic, one bright spot in providing funding is acquisitions—though even that vital
M&A activity a bright spot in funding for biotech, expert tells 2023 BIO-Europe Read More »
Cardiovascular disease (CVD) is the leading cause of death worldwide and is responsible for over 900,000 deaths in the U.S. annually—and hypercholesterolemia, or elevated
A promising oral pill for ‘bad cholesterol’ is exciting news for heart patients Read More »
Remarks from Dr. Ted W. Love, Chairman of the Biotechnology Innovation Organization (BIO) and former President and CEO of Global Blood Therapeutics, as prepared
Dr. Ted W. Love: How to reframe the narrative about biotech – and put patients first Read More »
Amgen Inc., an Advocate level sponsor of the 2023 BIO Patient & Health Advocacy Summit, provided their approval to share this previously published article
The U.S. Food and Drug Administration (FDA) has approved TIBSOVO (ivosidenib) as a treatment for a rare blood cancer, the agency said in an
Rare blood cancer drug wins FDA approval Read More »
Dr. Mary-Ann Etiebet, Associate Vice President, Health Equity, Merck, has more than two decades of experience working across the public and private sectors to
Turning insights into action: building a U.S. health system that delivers for all women Read More »
